Sep 7, 2016 | By Tess

3D bioprinting company Organovo has just announced that it has launched its latest bioprinted product, ExVive Human Kidney, which it will also begin commercial contracting for. In the wake of the announcement, the company has seen an impressive increase of 7% in premarket shares. The ExVive Human Kidney marks Organovo’s second 3D bioprinted tissue service, the first being the ExVive Human Liver, which was introduced in 2015.

ExVive Human Kidney, a 3D bioprinted proximal tubule model, will allow for clients and researchers to better study the effects that drugs and certain treatments have on the human kidney, effectively opening the doors for advanced drug discovery and development. So far, a number of commercial orders for the innovative product have already been placed with Organovo.

According to a press release, the 3D bioprinting company is also already collaborating with a number of toxicology panels and transporter studies as part of an early access program for their new product. Two of the collaborations are reportedly with global, top 25 pharmaceutical companies (which have so far remained unnamed). Information about the new product was presented this week at EUROTOX 2016 in Seville, Spain, a conference for the Association of European Toxicologists and European Societies of Toxicology. More information about the ExVive Human Kidney is expected to be released in upcoming weeks as well, at the 12th Annual Applied Pharmaceutical Analysis Meeting.

Here’s what we know about the 3D bioprinted kidney so far:

ExVive Human Kidney has effectively demonstrated a number of functionalities that make it extremely valuable for preclinical testing, such as proximal tube function for more than four weeks and a tissue-like complexity that facilitates the detection of injury, compensation, and recovery. The 3D printed tissue service has also demonstrated key transformer functions that allow users to assess kidney toxicity and drug interactions, and a number of other useful functions.

Keith Murphy, chairman and CEO of Organovo, said of the new product: “The powerful data Organovo is releasing on the ExVive Kidney Tissue demonstrates significant potential value for our pharmaceutical customers. The compelling symphony of transporter function and the demonstration of a response to a known toxicant boost our excitement as we bring to market an advanced way to  investigate preclinical kidney toxicity of new drug candidates.”

With their newest tissue service, Organovo has stated that it expects its annual revenue to grow into tens of millions of dollars. More precisely, the 3D bioprinting company expects to generate revenues up to $4 to $6 million in fiscal 2017. According to the press release for investors, “This kidney revenue opportunity is expected to be accretive to previous market projections for liver tissue, which are of similar magnitude.”

Organovo has made a name for itself within the 3D bioprinting industry for its innovative and disruptive bioprinted tissue services. Both the ExVive Human Kidney and Liver products offer the unique opportunity for pharmaceutical researchers to replicate complex cell-cell interactions and elements of tissue architecture to test and determine the effects of drugs on the organ. The company’s 3D bioprinted tissues have opened the doors for more rapid and cost efficient drug discovery process.

As of writing, ONVO stock is up 5.33% at $4.15.




Posted in 3D Printer Company



Maybe you also like:


Leave a comment:

Your Name:


Subscribe us to Feeds twitter facebook   

About provides the latest news about 3D printing technology and 3D printers. We are now seven years old and have around 1.5 million unique visitors per month.

News Archive